logo

For the Inventor, By the Inventor

Toorak, Australia

Antisense Therapeutics Limited

Calculating rank
USPTO Granted Patents = 17

% Expired Patents = 58.8



Forward Citations = 16

Loading Chart...
Loading Chart...

20 inventors (with patents filed for the assignee):

goldMedal George Tachas (14 out of 15 patents)

silverMedal Kenneth W Dobie (7 out of 76 patents)

bronzeMedal Ravi Jain (4 out of 22 patents)

4.  Christopher Belyea (3 out of 3 patents)

5.  Mark Heffernan (3 out of 3 patents)

6.  Ety Klinger (2 out of 11 patents)

7.  Shoshi Tessler (2 out of 2 patents)

8.  Mark Paul Diamond (2 out of 2 patents)

9.  Jeffrey R Crosby (1 out of 9 patents)

10.  Yong-Mi Kim (1 out of 1 patent)

11.  Christopher John Wraight (1 out of 5 patents)

12.  Nicholas M Dean (1 out of 54 patents)

13.  Lynne Maree Atley (1 out of 1 patent)

14.  Hussein Hallak (1 out of 4 patents)

15.  James G Karras (1 out of 20 patents)


17 patents:

1. 11976281 - Therapeutic uses and methods (2024-05-07),
2. 11891606 - Methods for treating multiple sclerosis using antisense oligonucleotides (2024-02-06),
3. 11041156 - Mobilizing leukemia cells (2021-06-22),
4. 9988635 - Modulation of growth hormone receptor expression and insulin-like growth factor expression (2018-06-05),
5. 9821034 - Combination therapy (2017-11-21),
6. 9717778 - Combination therapy (2017-08-01),
7. 9371530 - Modulation of growth hormone receptor expression and insulin-like growth factor expression (2016-06-21),
8. 9084770 - Modulation of insulin like growth factor I receptor expression in cancer (2015-07-21),
9. 8765700 - Topical administrations of antisense compounds to VLA-4 for the treatment of respiratory conditions (2014-07-01),
10. 8759314 - Methods for treating multiple sclerosis using antisense oligonucleotides (2014-06-24),
11. 8637484 - Modulation of growth hormone receptor expression and insulin-like growth factor expression (2014-01-28),
12. 8623836 - Modulation of growth hormone receptor expression and insulin-like growth factor expression (2014-01-07),
13. 8415314 - Methods for treating multiple sclerosis using antisense oligonucleotides (2013-04-09),
14. 8299039 - Modulation of growth hormone receptor expression and insulin-like growth factor expression (2012-10-30),
15. 8217017 - Modulation of insulin like growth factor I receptor expression (2012-07-10),
Company Overview
Antisense Therapeutics Limited is a biotechnology company based in Toorak, Australia, specializing in the development of innovative therapies targeting serious medical conditions. The company focuses on antisense technology, which involves the design of molecules that can modulate gene expression, offering potential treatments for diseases such as Duchenne muscular dystrophy and multiple sclerosis. Through its research and development efforts, Antisense Therapeutics aims to advance therapeutic options and improve patient outcomes in the field of genetic disorders.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

Antisense Therapeutics Limited USPTO Patent Assignee Logo
17 Patents

#2 in Toorak

#213 in Australia

#35,974 in the World

Toorak, AU
Toorak, Australia

Antisense Therapeutics Limited

Forward Citations = 16

20 inventors:

goldMedal George Tachas (14 out of 15 patents)

silverMedal Kenneth W Dobie (7 out of 76 patents)

bronzeMedal Ravi Jain (4 out of 22 patents)

4.  Christopher Belyea (3 out of 3 patents)

5.  Mark Heffernan (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Antisense Therapeutics Limited. Retrieved from https://idiyas.com/company/antisense-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…